Medtronic Claims Share Gains In Cardiovascular And Neurostim

The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.

Isometric Business people pushing cubes
• Source: shutterstock.com

Medtronic has mitigated the impact of COVID-19 on its revenues by taking market share from competitors in key markets, including neurostimulation, drug-eluting stents, cardiac rhythm management and robotic spine surgery.

“As we head into our fourth quarter, we’re bullish on the recovery and our ability to return to growth and...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Strategy

More from Business